Diagnostic testing for small fiber neuropathy. SFPN is characterized by loss of sensation (thermal and pinprick hypoesthesia) and positive sensory symptoms (burning pain, allodynia, hyperalgesia). Clinical neurological examination and routine neurophysiologic tests are often insufficiently sensitive, but skin biopsy and recent availability of normative reference values are of proven value in the diagnosis of damaged small nerve fibers (Lauria G, Lombardi R. Small fiber neuropathy: is skin biopsy the holy grail? Curr Diab Rep 2012 Aug; 12(4):384-92 
COATS SYNDROME IN FACIOSCAPULOHUMERAL DYSTROPHY TYPE 1
Investigators at University of Rochester Medical Center, NY; Hopital Archet-CHU de Nice, France; and Albert Einstein College of Medicine, NY, studied the frequency of Coats syndrome and its association with D4Z4 contraction size in 408 patients identified with facioscapulohumeral dystrophy type 1 (FSHD1). Three patients (0.8%) had a history of Coats disease, and 14 patients had FSHD and Coats syndrome confirmed by ophthalmologic examination. Median age at diagnosis of Coats syndrome was 10 years. The median D4Z4 fragment size was 13 kilobases. Close surveillance for retinal complications is recommended in FSHD1 patients with D4Z4 fragments <15kb. COMMENT. Coats disease, characterized by exudative retinitis and telangiectases of the retina, with slow progression to retinal detachment, may occur alone as an idiopathic form, unilateral, in males with onset at age 1-20 years, or as a syndrome, associated with FSHD1 and high-frequency hearing loss. FSHD1 is caused by a loss of D4Z4 repeat units on chromosome 4q35. Coats disease in the FSHD-associated syndrome is bilateral, it occurs at any age, and most frequently in female patients with FSHD and large contractions (allele size <15 kb). Contraction size (<15 kb) rather than age or FSHD severity should determine the need for annual retinal examinations for retinal vascular involvement and possible surgery. An early sign of Coats disease is a yellow-eye in flash photography, a reflection off cholesterol deposits in retinal blood vessels.
Coats disease is named after George Coats (Coats G. 
SMA TYPE III MIMICS MUSCULAR DYSTROPHY
Researchers at the National Neuroscience Institute, Riyadh, Saudi Arabia, report a series of 8 patients with type III spinal muscular atrophy who were referred with a diagnosis of muscular dystrophy. Developmental milestones were normal until early juvenile or teens years when they showed a slowly progressive proximal weakness involving limb-girdle muscles. A clumsy gait was associated with frequent falls and difficulty in climbing stairs. Seven patients were products of consanguineous marriage. Hypertrophy of calves in 3 patients contrasted with generalized muscle wasting. Tongue fasciculation occurred in 2 patients, deep tendon reflexes were diminished in 7, and spinal scoliosis developed in 5. Muscle biopsy had nonspecific myopathic features in 3 patients, and nerve conduction studies showed normal, mildly neurogenic or myopathic changes. Serum creatine kinase levels varied from normal to significantly elevated. The diagnosis of SMA III was confirmed by gene testing where deletions of exon 7 were detected in all patients. COMMENT. In the diagnosis of SMA type III, the presence of dystrophic features such as calf muscle hypertrophy, limb-girdle muscle weakness, elevated serum CPK, and myopathic or dystrophic muscle biopsy findings will sometimes lead to confusion with muscular dystrophy. Diagnosis is confirmed with a molecular genetic polymerase chain reaction-based test for 5q telomeric SMN1 mutation.
VASCULAR DISORDERS INTRACEREBRAL HEMORRHAGE, ACUTE SYMPTOMATIC SEIZURES, AND EPILEPSY
Investigators at Yale University School of Medicine, New Haven, CT; Children's Hospital of Philadelphia; Vanderbilt University, Nashville, TN; and Johns Hopkins University, studied the incidence and risk factors for seizures and epilepsy in 73 children with spontaneous intracerebral hemorrhage (ICH) including 20 perinatal subjects (>37 weeks gestation to 28 days) and 53 aged >28 days to <18 years at presentation. Acute symptomatic seizures occurred in 35 subjects (48%); they were a presenting symptom of ICH in 12 perinatal (60%) and 19 childhood (36%) subjects, and they occurred after
